Azalea Therapeutics, Inc.

Azalea Therapeutics, Inc. is a US-based biotechnology firm focused on developing innovative therapies for B-cell malignancies and autoimmune diseases, utilizing advanced CAR-T technology. Founded in 2023 by Jenny Hamilton (CEO), Connor Tsuchida, Abdullah Syed, Jennifer Doudna, Justin Eyquem, and Michael Fischbach and headquartered in Berkeley, US, Azalea Therapeutics, Inc. specializes in CAR-T therapies for treating various diseases.

The company was established to address significant unmet medical needs in oncology and autoimmune disorders. It has successfully raised a total of USD 65. 00 mn across its funding rounds, with the latest Seed round of USD 17. 00 mn completed on November 4, 2025.

The firm has secured 2 funding deals to date. Azalea Therapeutics, Inc. focuses on developing in vivo CAR-T therapies, primarily targeting B-cell malignancies and autoimmune diseases. Their flagship product is a CD19-based therapeutic approach designed to enhance patient outcomes.

The company aims to provide effective solutions for patients suffering from complex medical conditions, leveraging its expertise in gene therapy and immunology. Azalea Therapeutics, Inc. is currently in the early stages of revenue generation, focusing on funding and development rather than established sales. The company is positioned to create revenue streams as it progresses its therapies into clinical trials and potentially to market.

Azalea Therapeutics, Inc. plans to utilize its recent Seed funding to advance its CD19-based in vivo CAR-T therapy into clinical trials, specifically targeting B-cell malignancies and autoimmune diseases. Additionally, the firm intends to develop new programs aimed at treating multiple myeloma and solid tumors. The funding will also support the company's strategic initiatives for future product launches and potential market expansion.